Chardan Capital Reiterates Buy Rating for SAB Biotherapeutics (NASDAQ:SABS)

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $25.00 price target on the stock.

SABS has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a report on Wednesday. Craig Hallum started coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 price target for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock opened at $2.17 on Wednesday. SAB Biotherapeutics has a 52 week low of $2.00 and a 52 week high of $6.30. The company’s 50-day moving average price is $3.61 and its two-hundred day moving average price is $3.12. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. As a group, analysts expect that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC bought a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned 0.21% of SAB Biotherapeutics at the end of the most recent reporting period. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.